Given that cell line collections are not representative of BRCA1‐ and BRCA2‐altered patient tumour response to PARP inhibitors, we hypothesised that an isogenic model hosting specific gene alterations would be more appropriate to explore cellular responses to PARP inhibitor treatment. This evidence concerns the gene BRCA2 and neoplasm.